Chronic Obstructive Pulmonary Disease (COPD)IMPACT-BPCONCT06872450
Informational Tool for Smoking Cessation in COPD Patients
An observational study of Chronic Obstructive Pulmonary Disease (COPD), run by Hopital Nord Franche-Comte at 1 site in France.
Trial summary
Chronic obstructive pulmonary disease (COPD) is a lung disease that affects nearly 8% of the adult population and causes 18,000 deaths per year in France. The most frequent cause of this pathology is smoking. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease (COPD)
- What is being tested?
- informational intervention
- How many people
- 15 participants
- Where
- 1 siteFrance
- Study dates
- 14 Feb 2025to 9 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: People suffering from chronic obstructive pulmonary disease (COPD) stage 2/3
Who may be able to join
- People suffering from chronic obstructive pulmonary disease (COPD) stage 2/3
- People treated at HNFC
- Smokers
Who cannot join
- People with cognitive disorders compromising comprehension and completion of the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Implementation and Impact Study of an Informational Tool for Smoking Cessation in COPD Patients
Chronic obstructive pulmonary disease (COPD) is a lung disease that affects nearly 8% of the adult population and causes 18,000 deaths per year in France. The most frequent cause of this pathology is smoking. COPD patients who stop smoking have a better quality of life, a marked a significant slowdown in disease progression and an increased life expectancy. Investigators propose to carry out a quantitative study among patients smokers suffering from COPD, by setting up a tool in the form of an motivational intervention specific to this population.
Read the detailed description
implementing a tool in the form of an informational intervention with a specific motivational intervention
- Being tested
- informational intervention
- Keywords
- informational and motivational tool
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
informational interventionOther
informational intervention
| Study group | Role | What they receive |
|---|---|---|
| informational intervention | informational intervention Receives: Other: informational intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
motivational effectiveness
Motivation to stop smoking (QMAT test)
Measured: 60 days
motivational effectiveness
Anxio-depressive state (HAD scale)
Measured: 60 days
motivational effectiveness
Degree of dependence (Fagerström test)
Measured: 60 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2025
- Study start14 Feb 2025
- Primary completion9 May 2025
- Study completion9 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Obstructive Pulmonary Disease (COPD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hopital Nord Franche-Comte
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06872450
- Sponsor's protocol ID
- 2024-11-IMPACT BPCO
- Acronym
- IMPACT-BPCO
- Status last verified
- Aug 2025
- First submitted
- 25 Feb 2025
- Last updated
- 8 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementation and Impact Study of an Informational Tool for Smoking Cessation in COPD Patients
- ClinicalTrials.gov ID
- NCT06872450
- Acronym / sponsor ID
- IMPACT-BPCO / 2024-11-IMPACT BPCO
- Keywords
- informational and motivational tool
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Hopital Nord Franche-ComteUniversity, hospital or other
- Study start
- 14 Feb 2025 (actual)
- Primary completion
- 9 May 2025 (actual)
- Study completion
- 9 May 2025 (actual)
- First posted
- 12 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic obstructive pulmonary disease (COPD) is a lung disease that affects nearly 8% of the adult population and causes 18,000 deaths per year in France. The most frequent cause of this pathology is smoking. COPD patients who stop smoking have a better quality of life, a marked a significant slowdown in disease progression and an increased life expectancy. Investigators propose to carry out a quantitative study among patients smokers suffering from COPD, by setting up a tool in the form of an motivational intervention specific to this population.
Detailed description
implementing a tool in the form of an informational intervention with a specific motivational intervention
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| informational intervention | – | Other: informational interventioninformational intervention |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- People suffering from chronic obstructive pulmonary disease (COPD) stage 2/3
Key inclusion criteria (3 listed)
- People suffering from chronic obstructive pulmonary disease (COPD) stage 2/3
- People treated at HNFC
- Smokers
Key exclusion criteria (1 listed)
- People with cognitive disorders compromising comprehension and completion of the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| informational interventioninformational intervention | Other | informational intervention |
Primary outcome
motivational effectiveness
Time frame: 60 days
Motivation to stop smoking (QMAT test)
motivational effectiveness
Time frame: 60 days
Anxio-depressive state (HAD scale)
motivational effectiveness
Time frame: 60 days
Degree of dependence (Fagerström test)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Chronic Obstructive Pulmonary Disease (COPD)
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
RecruitingPhase 2
Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD
Chronic Obstructive Pulmonary Disease
Recruiting
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
COPD, Chronic Obstructive Pulmonary Disease
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Active, not recruitingPhase 2
Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD
COPD (Chronic Obstructive Pulmonary Disease)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Obstructive Pulmonary Disease (COPD), run by Hopital Nord Franche-Comte at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
motivational effectiveness (time frame: 60 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Aug 2025.